A big concern for the pharmaceutical industry is the willingness of insurance companies to continue to reimburse at a level significant enough for pharmaceutical and biotech companies to continue heavy investment into R&D, and thus drive U.S. medical innovation. By Rob Wright

Kevin Nepveux, VP of global technology services with in Pfizer Global Supply shares his insights about continuous manufacturing and how Pfizer is deploying continuous and batch processes as a hybrid approach toward improving manufacturing efficiencies. Kevin Nepveux says “I think one of the best ways to go about implementing CM processes is to develop the analytics in line with the application.”

When launching a start-up in the life sciences industry the question of going public or private could be a struggle. A key driver for the decision to go public is the availability of funding sources and management’s experiences and relationships, says Punit Dhillon, president and CEO of OncoSec Medical Inc.

I recently had the pleasure of taking my son to start his freshman year in college at Wooster.. As we drove through campus, we were greeted by cheering students dressed in yellow T-shirts, welcoming us to the school. People were passing out ice cream, food, drinks, while upbeat music played over loud speakers.

I recently had the opportunity to meet a former CEO of a top 10 pharma company. During our meeting, we discussed the concept of “adapt or die,” something they know a little bit about from personal experience. By Rob Wright

When ATMI’s (NASDAQ: ATMI) CEO, Doug Neugold, gave his keynote presentation at this year’s international single-use summit in Washington, D.C., it may have seemed a bit out of place to some people. By Rob Wright

Bharat Biotech pledged to sell Rotovac for the rotavirus for $1 a dose to compete with GSK and Merck, if they make it cheaper can they make it safer?

In 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a number of strategic moves, such as the dissolution of the 23-year, 50/50 joint venture with Abbott, known as TAP Pharmaceuticals, and acquiring Millennium Pharmaceuticals (2008) and Nycomed. These changes strengthened Takeda’s position in two of the largest pharmaceutical markets outside of Japan (U.S. and EU), placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?

Since its opening in 2008, the Michigan Life Science Innovation Center (MLSIC) has incubated 15 companies, which have created 92 jobs and attracted more than $75 million in investment in southeast Michigan. By Rob Wright